Monitoring the immune response of anti-SARS-CoV2 vaccinated individuals and COVID-19-positive patients – a prospective monocentric non-interventional observational study

• Conditions: U07.1; U08.9; COVID-19, virus identified; Personal history of COVID-19, unspecified

• Registration Number: DRKS00024551
• Lead Sponsor: Städtisches Klinikum Dessau. Medizinische Hochschule Brandenburg Theodor Fontane

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 700

Inclusion Criteria

Employees of the Dessau Medical Center, COVID-19 patients of the Dessau Medical Center, hemato-oncological patients of the Dessau Medical Center

Exclusion Criteria

Persons, who do not confirm their participation at the study

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SARS-CoV2 antibody titre in serum - blood collection 2, 4, 8 12, 16, 32, 48 weeks after the second vaccination

Secondary Outcome Measures

Name	Time	Method
Blood count, CRP, BSG, C3, C4, circulating immune complexes, IL-6, IL-2 receptor, TNF-a, IL-4, IL-13 through blood control 2, 4, 8 12, 16, 32, 48 weeks after the second vaccination<br>General symptoms, dermatological findings 2, 4, 8 12, 16, 32, 48 weeks after the second vaccination in the staff and the dermato-oncological patients of the Dessau Medical Center<br>General symptoms, dermatological findings during COVID-19 infection and 2, 4, 8 12, 16, 32, 48 weeks after infection detection in COVID-19 patients of the Dessau Medical Center